EUVIMEDEUVIMED entdecken
Open Access

RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside

Iqra Ali, Juhui Qiu, Wai San Cheang, Guixue Wang iD, Suowen Xu iD

Research · 01.01.2026 · 9

DOI: 10.34133/research.1288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research, online erschienen am 19.05.2026. Verfasst von Iqra Ali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Jinfeng Lab Fundamental Research Funds, Chongqing, Fundamental Research Funds for the Central Universities.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid accumulation drives the development of atherosclerotic cardiovascular disease, the leading cause of death worldwide. The liver is the primary target for lipid-lowering therapies due to its central role in lipid metabolism. Despite advances in small-molecule drugs, substantial residual cardiovascular risk remains. Recent clinical evidence in 2026 reaffirms the “lower is better” paradigm, showing that achieving very low low-density lipoprotein cholesterol (

Autor:innen und Institutionen

  • Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, College of Bioengineering, Chongqing University, Chongqing 400030, C…
  • Institute of Panvascular Biology, JinFeng Laboratory, Chongqing 401329, China.
  • State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, SAR, China.
  • Department of Endocrinology and Metabolism, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technolo…
  • Anhui Provincial Key Laboratory of Metabolic Health and Panvascular Diseases, Hefei 230001, China.

ORCID-Profile: Guixue Wang, Suowen Xu

Förderung

  • National Natural Science Foundation of China
  • Jinfeng Lab Fundamental Research Funds, Chongqing
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Ali, I., Qiu, J., Cheang, W. S., Wang, G., & Xu, S. (2026). RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside. Research, 9. https://doi.org/10.34133/research.1288

Vancouver

Ali I, Qiu J, Cheang WS, Wang G, Xu S. RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside. Research. 2026;9. doi:10.34133/research.1288

BibTeX
@article{Ali2026,
  author = {Ali, Iqra and Qiu, Juhui and Cheang, Wai San and Wang, Guixue and Xu, Suowen},
  title = {RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside},
  journal = {Research},
  year = {2026},
  volume = {9},
  doi = {10.34133/research.1288}
}
Kostenlos starten →